Company Announcements IONICON Analytik opened a North American subsidiary in October 2011 in New Jersey. Perten Instruments Americas formed in November 2011 a dedicated process instrumentation department. In November 2011, Scientific Industries acquired Fluorometrix and its license from the University of Maryland, Baltimore County, and related sublicenses for $260,000 in cash, 135,135 shares of common […]
Company Announcements The National Institute of Bioprocessing Research and Training, Ireland, and GE Healthcare Life Sciences announced a joint research collaboration in September 2011 to develop new, robust and reproducible biochemical assays for the analysis of the biological activity of therapeutic monoclonal antibodies. An investment of $0.5 million will be made in the first year […]
Company Announcements New Brunswick Scientific, an Eppendorf company, laid off 184 workers in New Jersey in November 2011, according to njbiz.com. Misonix sold its Laboratory and Forensic Safety Products business, which had fiscal 2011 revenues of $2.1 million, to Mystaire in October 2011 for $1.5 million plus a potential payment. The business provides ductless fume […]
Company Announcements Hudson Control Group named Wagner Medical and Pharmaceutical its new sales representative for continental Europe in November 2011. In November 2011, Tecan appointed Martin Brusdeilins as head of its Development & Operations Division. He also retained his current position as head of the Science & Technology unit. He replaces Jürg Dübendorfer, who will […]
Canadian R&D spending in 2011 is expected to have totaled CAD 29.9 billion ($29.6 billion), which is 2.0% higher than initial 2010 R&D figures but 1.9% less than in 2008. Business enterprise spending is expected to have grown 5.0% to make up 52% of R&D spending. The sector contributed 47% of R&D funding for a […]
India’s INR 90,000 crore ($19.0 billion = INR 45.17 = $1) generic drug industry and growth of its pharmaceutical market over the past few years has made it an ideal place for foreign drug firms to invest. However, recent compliance and quality issues at Indian firms have made global drug companies wary of future acquisitions […]
The Korean Health and Welfare Ministry announced that by 2020, the government will spend KRW 146 billion ($126 million) to subsidize drug firms. The funding aims to make Korea the seventh-largest drug industry by increasing its share of the export market from 0.2% to 5.4%. Under the plan, 10 new drugs will be produced by […]
To increase sluggish returns on investment, pharmaceutical and biotechnology firms are relying more on CROs, according to a new report from the Economist Intelligence Unit (EIU). In the last two years, pharmaceutical and biotech firms have established 22 major partnerships with CROs, which now account for 40% of discovery and development (D&D). In September 2011, […]
The percentage of NIH research grant applications that were funded fell 3% to a record low of 18% in fiscal 2011. The decline is mainly due to the funding of continuing multiyear R01 grants. Funding such grants cost the NIH an additional $189 million and accounted for 78% of available grant money. Another factor was […]
According to the Industrial Research Institute’s (IRI) 28th annual “R&D Trends Forecast,” 53% of respondents plan to spend the same amount on R&D in 2012 as last year. The IRI surveyed R&D managers at 104 firms in multiple industries in July and August 2011. R&D budget increases of 2.5% to 5% are expected by 22% […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
